Document Detail


Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
MedLine Citation:
PMID:  19932779     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) showed that the angiotensin receptor blocker telmisartan 80 mg was not inferior to the angiotensin-converting enzyme inhibitor ramipril 10 mg, and the combination no more effective than ramipril alone, in decreasing morbidity and mortality in patients with cardiovascular disease or high-risk diabetes. Although therapy targeting angiotensin II is known to decrease left ventricular (LV) mass and volume, the relative influence of angiotensin-converting enzyme inhibitor inhibitors and angiotensin receptor blocker, and their combination, on the heart remains unclear in this population. Magnetic resonance imaging was performed in 287 patients enrolled in ONTARGET, across 8 centers in 6 countries, at randomization and after 2-year treatment (90, 100, and 97 patients in the ramipril, telmisartan, and combination therapy groups, respectively). Baseline patient characteristics showed higher frequencies of coronary artery disease, Asian ethnicity, and use of statins and beta blockers than the main ONTARGET trial. LV mass decreased in all groups (p <0.0001 for each), but there were no significant differences in change in LV mass or volume among groups, except that LV mass index decreased more on combination versus telmisartan (p = 0.04). Key determinants of LV mass decrease were a history of hypertension (p = 0.03), baseline mass (p <0.0001), and decrease in systolic blood pressure (p <0.0001). The best magnetic resonance imaging predictor of composite events was end-systolic volume (p <0.0001). In conclusion, telmisartan and ramipril had similar effects on LV mass and volume, and combination therapy was not more effective, in high-risk patients with cardiovascular disease. These results are consistent with the major outcome findings of the main ONTARGET study.
Authors:
Brett R Cowan; Alistair A Young; Craig Anderson; Robert N Doughty; Rungroj Krittayaphong; Eva Lonn; Thomas H Marwick; Chris M Reid; John E Sanderson; Roland E Schmieder; Koon Teo; Angela K Wadham; Stephen G Worthley; Cheuk-Man Yu; Salim Yusuf; Garry L Jennings;
Related Documents :
9159649 - Pressure-interval relationship characterizes left ventricular irregular beat contractil...
2930399 - Lung volume of meat-type chickens.
16214409 - Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic...
2032409 - Noninvasive detection of the morphologic and hemodynamic changes during normal pregnancy.
2521539 - Doppler echocardiographic evaluation of left ventricular diastolic filling in isolated ...
8615319 - Mitral valve repair is superior to valve replacement for the early preservation of card...
23690989 - Factors associated with blood pressure control in hypertensive patients with coronary h...
3653529 - Effect of cisapride on the gastro-oesophageal function in normal human subjects.
9439779 - Effect of castration on renin-angiotensin system of hypertensive rats submitted to chro...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-10-14
Journal Detail:
Title:  The American journal of cardiology     Volume:  104     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-25     Completed Date:  2010-02-01     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1484-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Atherosclerosis / complications*
Benzimidazoles / therapeutic use*
Benzoates / therapeutic use*
Diabetes Complications / diagnosis,  drug therapy*
Drug Therapy, Combination
Female
Humans
Hypertension / drug therapy*
Hypertrophy, Left Ventricular / diagnosis*,  drug therapy*
Magnetic Resonance Imaging*
Male
Ramipril / therapeutic use*
Survival Analysis
Treatment Outcome
Ventricular Dysfunction, Left / drug therapy
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Benzimidazoles; 0/Benzoates; L35JN3I7SJ/Ramipril; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in pat...
Next Document:  Prognostic significance of QRS duration in patients with suspected coronary artery disease referred ...